ArticleBMC neurology2020
Prospective study of stress, depression and personality in myasthenia gravis relapses.
Article in BMC neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Efgartigimod improved health-related quality of life in generalized myasthenia gravis: results from a randomized, double-blind, placebo-controlled, phase 3 study (ADAPT).Journal of neurology · 2023Trial
- Exploring psychosocial experiences in clinically stable generalised Myasthenia Gravis: A thematic analysis.Journal of neuromuscular diseases · 2026Article
- Comorbidities and Treatment Patterns in People With Myasthenia Gravis in Denmark, Finland and Sweden: A Population-Based Observational Study.Muscle & nerve · 2026Observational
- Association between antibody status and exacerbation in patients with myasthenia gravis who achieved minimal manifestation or better status.Journal of neurology · 2025Article
- Postmarketing adverse events of efgartigimod alfa: a real-world pharmacovigilance study based on the FAERS database.BMJ open · 2025Article
- Effect of the Administration of Cautionary Drugs on the Risk of Worsening Myasthenia Gravis: A Retrospective Matched Case-Control Study.Yonsei medical journal · 2025Article
- Myasthenia Gravis and Depression: A Multifaceted Exploration through Omics and Beyond.Alpha psychiatry · 2025Article
- Expert consensus recommendations for improving and standardising the assessment of patients with generalised myasthenia gravis.European journal of neurology · 2024Article
- Depression: A Contributing Factor to the Clinical Course in Myasthenia Gravis Patients.Medicina (Kaunas, Lithuania) · 2023Article
- Personality factors in patients with myasthenia gravis: A prospective study.Brain and behavior · 2023Article
- Is hypnotic assessment relevant to neurology?Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022Review
- Anti-titin antibody is associated with more frequent hospitalization to manage thymoma-associated myasthenia gravis.Frontiers in neurology · 2022Article
- Illness perception characteristics and influencing factors in adult patients with myasthenia gravis in China.Brain and behavior · 2022Article
- Myasthenia gravis and anxiety-depression states: an integrated clinical and Mendelian randomization study.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPsychopathology and personality traits may influence the course of autoimmune disorders. With this prospective longitudinal cohort study, we aimed to assess personality, stress and depression in myasthenia patients who relapse and those who remain stable or improve (non-relapsers).
methodWe collected data from 155 consecutive adult patients with confirmed MG attending the Neuromuscular Clinic, Toronto General Hospital, between March 2017 and July 2018, for this study. Patients were assessed at baseline and 6 months, or at the time of MG relapse. At both visits, the patients were assessed clinically and were asked to complete self-administered questionnaires for disease severity, chronic stress and depression. Personality type was assessed at baseline only. Relapsing patients were defined as those patients with MGII score increasing by more than 5.5 points from visit 1 to visit 2.
resultsRelapsers had higher baseline scores for depression (p = 0.01) and the change in disease severity correlated with the change in depression score (r = 0.2534, p = 0.0015, 95% CI: 0.098 0.3961). Higher levels of stress at baseline and neuroticism predicted higher relapse rates (p = 0.01 and p < .0001, respectively). In the linear regression model, with change of the MGII score as the dependent variable, change in depression scores (p = 0.0004) and age (p = 0.03) predicted change in disease severity.
conclusionsSince emotional factors and personality type may influence MG, attention to these factors might improve care in MG patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.